High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only

References

• Lukes R J, Butler J J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26: 1063–1083
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European – American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• Rudiger T, Ott G, Ott M M, Muller-Deubert S M, Muller-Hermelink H K. Differential diagnosis between classic Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and paragranuloma by paraffin immunohistochemistry. Am J Surg Pathol 1998; 22: 1184–1191
   PubMed Web of Science ®Google Scholar
• Uherova P, Valdez R, Ross C W, Schnitzer B, Finn W G. Nodular lymphocyte predominant Hodgkin lymphoma. An immunophenotypic reappraisal based on a single-institution experience. Am J Clin Pathol 2003; 119: 192–198
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. World Health Organisation Classification of tumours: Pathology & genetics: Tumours of haematopoietic and lymphoid tissues. IARC, LyonFrance 2001
   Google Scholar
• Landberg T, Larsson L E. Hodgkin's disease. Retrospective clinico-pathologic study in 149 patients. Acta Radiol Ther Phys Biol 1969; 8: 390–414
   PubMed Web of Science ®Google Scholar
• Keller A R, Kaplan H S, Lukes R J, Rappaport H. Correlation of histopathology with other prognostic indicators in Hodgkin's disease. Cancer 1968; 22: 487–499
   PubMed Web of Science ®Google Scholar
• Hansmann M L, Zwingers T, Boske A, Loffler H, Lennert K. Clinical features of nodular paragranuloma (Hodgkin's disease, lymphocyte predominance type, nodular). J Cancer Res Clin Oncol 1984; 108: 321–330
   PubMed Web of Science ®Google Scholar
• Franklin J, Tesch H, Hansmann M L, Diehl V. Lymphocyte predominant Hodgkin's disease: pathology and clinical implication. Ann Oncol 1998; 9(Suppl 5)S39–S44
   PubMedGoogle Scholar
• Hakvoort-Cammel F G, Buitendijk S, van den Heuvel-Eibrink M, Hahlen K. Treatment of pediatric Hodgkin disease avoiding radiotherapy: Excellent outcome with the Rotterdam-HD-84-protocol. Pediatr Blood Cancer 2004; 43: 8–16
   PubMed Web of Science ®Google Scholar
• Poppema S, Kaiserling E, Lennert K. Hodgkin's disease with lymphocytic predominance, nodular type (nodular paragranuloma) and progressively transformed germinal centres—A cytohistological study. Histopathology 1979; 3: 295–308
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I, Hansmann M L, Franssila K, Harris M, Harris N L, Jaffe E S, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: Histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000; 96: 1889–1899
   PubMed Web of Science ®Google Scholar
• Nicholas D S, Harris S, Wright D H. Lymphocyte predominance Hodgkin's disease—An immunohistochemical study. Histopathology 1990; 16: 157–165
   PubMed Web of Science ®Google Scholar
• von Wasielewski R, Werner M, Fischer R, Hansmann M L, Hubner K, Hasenclever D, et al. Lymphocyte-predominant Hodgkin's disease. An immunohistochemical analysis of 208 reviewed Hodgkin's disease cases from the German Hodgkin Study Group. Am J Pathol 1997; 150: 793–803
   PubMed Web of Science ®Google Scholar
• Tefferi A, Zellers R A, Banks P M, Therneau T M, Colgan J P. Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease. J Clin Oncol 1990; 8: 1959–1965
   PubMed Web of Science ®Google Scholar
• Sandoval C, Venkateswaran L, Billups C, Slim M, Jayabose S, Hudson M M. Lymphocyte-predominant Hodgkin disease in children. J Pediatr Hematol Oncol 2002; 24: 269–273
   PubMed Web of Science ®Google Scholar
• Murphy S B, Morgan E R, Katzenstein H M, Kletzel M. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003; 25: 684–687
   PubMed Web of Science ®Google Scholar
• Karayalcin G, Behm F G, Gieser P W, Kung F, Weiner M, Tebbi C K, et al. Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment—The Pediatric Oncology Group experience. Med Pediatr Oncol 1997; 29: 519–525
   PubMedGoogle Scholar
• Hutchinson R J, Fryer C J, Davis P C, Nachman J, Krailo M D, O'Brien R T, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: Results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998; 16: 897–906
   PubMed Web of Science ®Google Scholar
• Nachman J B, Sposto R, Herzog P, Gilchrist G S, Wolden S L, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765–3771
   PubMed Web of Science ®Google Scholar
• Pellegrino B, Terrier-Lacombe M J, Oberlin O, Leblanc T, Perel Y, Bertrand Y, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—A Study of the French Society of Pediatric Oncology. J Clin Oncol 2003; 21: 2948–2952
   PubMed Web of Science ®Google Scholar
• Delabie J, Vandenberghe E, Kennes C, Verhoef G, Foschini M P, Stul M, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16: 37–48
   PubMed Web of Science ®Google Scholar
• Borg-Grech A, Radford J A, Crowther D, Swindell R, Harris M. A comparative study of the nodular and diffuse variants of lymphocyte-predominant Hodgkin's disease. J Clin Oncol 1989; 7: 1303–1309
   PubMed Web of Science ®Google Scholar
• Regula D P, Jr., Hoppe R T, Weiss L M. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. N Engl J Med 1988; 318: 214–219
   PubMed Web of Science ®Google Scholar
• Meignin V, Briere J, Brice P, Gisselbrecht C, Gaulard P, Janin A. Hodgkin disease with nodular lymphocytic predominance or type I (paragranuloma of Poppema – Lennert): A clinico-pathological entity. Study of 21 cases and review of the literature. Ann Pathol 2000; 20: 19–24
   PubMed Web of Science ®Google Scholar
• Chul S. Hodgkin's disease with lymphocyte predominance: Long-term results based on current histopathologic criter. Int J Rad Oncol Biol Physics 1999; 43: 241–467
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison L L, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334: 745–751
   PubMed Web of Science ®Google Scholar
• van Leeuwen F E, Klokman W J, Veer M B, Hagenbeek A, Krol A D, Vetter U A, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000; 18: 487–497
   PubMed Web of Science ®Google Scholar
• Hudson M M, Krasin M J, Kaste S C. PET imaging in pediatric Hodgkin's lymphoma. Pediatr Radiol 2004; 34: 190–198
   PubMed Web of Science ®Google Scholar
• Rehwald U, Schulz H, Reiser M, Sieber M, Staak J O, Morschhauser F, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003; 101: 420–424
   PubMed Web of Science ®Google Scholar
• Keilholz U, Szelenyi H, Siehl J, Foss H D, Knauf W, Thiel E. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 monoclonal antibody) and interleukin-2. Leuk Lymphoma 1999; 35: 641–642
   PubMed Web of Science ®Google Scholar
• Ekstrand B C, Lucas J B, Horwitz S M, Fan Z, Breslin S, Hoppe R T, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101: 4285–4289
   PubMed Web of Science ®Google Scholar
• Chan W C. Cellular origin of nodular lymphocyte-predominant Hodgkin's lymphoma: immunophenotypic and molecular studies. Semin Hematol 1999; 36: 242–252
   PubMed Web of Science ®Google Scholar
• Boulanger E, Meignin V, Leverger G, Solal-Celigny P. Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin's disease. Ann Oncol 2003; 14: 171
   PubMed Web of Science ®Google Scholar
• Diehl V, Sextro M, Franklin J, Hansmann M L, Harris N, Jaffe E, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17: 776–783
   PubMed Web of Science ®Google Scholar
• Miettinen M, Franssila K O, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51: 2293–2300
   PubMed Web of Science ®Google Scholar